The application is now open for the Flinn Foundation’s Bioscience Entrepreneurship Program.Continue reading
Category Archives: AZBio News
With November Renewal Dashboard, AHCCCS Adds Map of Areas at Risk of Disenrollment
PHOENIX – The Arizona Health Care Cost Containment System (AHCCCS) released its monthly Medicaid renewal data dashboard detailing progress through November and launched a new zip code map detailing areas at highest risk of discontinuance.Continue reading
Helios Education Foundation Extends Support of TGen Bioscience Leadership Academy Through 2028
Applications for summer 2024 program for rising juniors and seniors opened December 11, 2023.
Continue reading
Applications are open for Helios Scholars at TGen
Do you want to experience what it’s really like to be a scientist?
Helios Scholars at TGen is a paid, eight-week summer internship program in biomedical research open to incoming and continuing undergraduate, graduate, and medical school students who have studied at an Arizona high school, college, or university. Interns work full-time on a research project under the mentorship of a TGen scientist to unravel the genetic components of diabetes, neurological disease and cancer. At TGen North in Flagstaff, interns focus their summer research on public health and pathogens such as Valley Fever and antibiotic resistant bacteria. Applications close Wednesday, Feb. 7.Continue reading
IMHR Funding Announcement Winter 2024 Grants Program
The Institute for Mental Health Research (IMHR) is pleased to announce the Winter 2024 grant competition in which we will award up to $250,000 in grants with individual awards of up to $50,000 for innovative mental health research. These grants are available to credentialed investigators in the state of Arizona associated with any recognized research or health institution in the state. This funding mechanism is specifically meant to seed, through substantial pilot activity, research that will lead to significant subsequent funding from federal agencies or major national philanthropic organizations, or to make a durable positive impact on existing mental health programming in Arizona.Continue reading
Life365 Continues to Expand Its Virtual Care Platform with the Acquisition of the PillDrill Smart Medication Tracking System
SCOTTSDALE, Ariz. – December 6, 2023 – Life365 Health a leader in virtual care, remote patient monitoring (RPM) and patient engagement announced today the acquisition of PillDrill, award-winning smart medication tracking system. With this acquisition, the Life365 Virtual Care Platform continues to differentiate itself in the digital health space, by providing integrated tools that move proactive and personalized care closer to individuals at home.Continue reading
AZBio CEO Shares Insights on the Impact of Arizona’s Bioindustry with Bob Roth on the Health Futures Podcast
In a recent episode of the radio show Health Futures, Taking Stock in You, hosted by Bob Roth, the guest was Joan Koerber-Walker, CEO and President of the Arizona Bioindustry Association (AZBio). The discussion revolved around Arizona’s transformation into a prominent hub for bioscience companies over the past two decades.Continue reading
Life365 Announces Strategic Acquisition of AffirmXH to Enhance Health Solutions
PHOENIX, Ariz. – December 5, 2023 – Life365, a leader in transforming healthcare through innovative solutions, announce today the acquisition of AffirmXH, a company renowned for its advanced biometric data analysis and no-code digital treatment platforms. The acquisition was completed under the LifeConnect division, and signifies a major step in expanding their reach in health monitoring.Continue reading
Industry Leader and Globally Recognized Patient Advocate John F. Crowley Appointed to Lead BIO as President & CEO
First Patient Enrolled in the PUERTA Phase 2A ARDS Clinical Trial: Treatment with Aqualung Therapeutics ALT-100 mAb
- A total of 14 PUERTA participating sites, 12 US and 2 Australian, in the Phase 2A trial of ALT-100 mAb in moderate to severe ARDS
- Aqualung awarded a $3M NIH R44 grant supporting the PUERTA Phase 2A Clinical Trial